We conclude, despite these limitations, that serum Fuc-Hpt levels can distinguish NASH from non-NASH patients and estimate the increase in hepatocyte ballooning scores of NAFLD patients with an accuracy superior to that of the M30 antigen in our patients. This evidence concerns the gene MRS2 and metabolic dysfunction-associated steatotic liver disease.